Were Hedge Funds Right About Souring On Pfizer Inc. (PFE)?

In This Article:

Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David Abrams, the resources they expend are second-to-none. This is especially valuable when it comes to small-cap stocks, which is where they generate their strongest outperformance, as their resources give them a huge edge when it comes to studying these stocks compared to the average investor, which is why we intently follow their activity in the small-cap space.

Pfizer Inc. (NYSE:PFE) shareholders have witnessed a decrease in hedge fund interest of late. Our calculations also showed that PFE isn't among the 30 most popular stocks among hedge funds.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren't comfortable with shorting stocks, you should at least avoid initiating long positions in our short portfolio.

Sander Gerber of Hudson Bay Capital
Sander Gerber of Hudson Bay Capital

We're going to view the fresh hedge fund action encompassing Pfizer Inc. (NYSE:PFE).

Hedge fund activity in Pfizer Inc. (NYSE:PFE)

Heading into the second quarter of 2019, a total of 53 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -10% from the previous quarter. The graph below displays the number of hedge funds with bullish position in PFE over the last 15 quarters. As you can see, hedge funds have been souring on Pfizer since the first quarter of 2016 when Pfizer shares were trading below $30.